about
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke AssociationPeroxiredoxin 5 (PRX5) is correlated inversely to systemic markers of inflammation in acute strokeFunctional polymorphisms in toll-like receptor 4 are associated with worse outcome in acute ischemic stroke patients.Weekend Discharge and Stroke Quality of Care: Get With The Guidelines-Stroke Data from a Comprehensive Stroke Center.Comparing perceived burden for Korean and American informal caregivers of stroke survivors.Prior antiplatelet therapy, platelet infusion therapy, and outcome after intracerebral hemorrhage.Intensive care unit management of the stroke patient.Plasma α-melanocyte stimulating hormone predicts outcome in ischemic stroke.Autoimmune responses to brain following stroke.Standardizing the structure of stroke clinical and epidemiologic research data: the National Institute of Neurological Disorders and Stroke (NINDS) Stroke Common Data Element (CDE) project.Anti-leukocyte antibodies: LeukArrest (Hu23F2G) and Enlimomab (R6.5) in acute stroke.Stroke, IL-1ra, IL1RN, infection and outcome.Modulation of the postischemic immune response to improve stroke outcome.Targeting the central nervous system inflammatory response in ischemic stroke.Anamnestic recall of stroke-related deficits: an animal model.Poststroke fatigue: hints to a biological mechanism.Do-not-attempt-resuscitation orders and prognostic models for intraparenchymal hemorrhageEarly statin use is associated with increased risk of infection after stroke.Full medical support for intracerebral hemorrhage.Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.Immune mediated diseases and immune modulation in the neurocritical care unitPalliative Care Needs in the Neuro-ICUResponse to psychosocial treatment in poststroke depression is associated with serotonin transporter polymorphismsHigher plasma fractalkine is associated with better 6-month outcome from ischemic stroke.Immunology of ischemic vascular disease: plaque to attack.Myelin basic protein autoantibodies, white matter disease and stroke outcome.Acute kidney injury is associated with increased hospital mortality after stroke.Severe stroke induces long-lasting alterations of high-mobility group box 1.Lymphocytes: potential mediators of postischemic injury and neuroprotection.Effect of Continuous Positive Airway Pressure on Stroke Rehabilitation: A Pilot Randomized Sham-Controlled Trial.Added Value of Vessel Wall Magnetic Resonance Imaging in the Differentiation of Moyamoya Vasculopathies in a Non-Asian CohortAssociation of serotonin transporter gene polymorphisms with poststroke depression.Sensitization and tolerization to brain antigens in stroke.The immunologic profile of adoptively transferred lymphocytes influences stroke outcome of recipients.Immunological consequences of ischemic stroke.Prognostic value of blood interleukin-6 in the prediction of functional outcome after stroke: a systematic review and meta-analysis.Inflammation and the Silent Sequelae of Stroke.Increased infections with β-blocker use in ischemic stroke, a β2-receptor mediated process?Poststroke Fatigue: Emerging Evidence and Approaches to Management: A Scientific Statement for Healthcare Professionals From the American Heart Association.The contribution of antibiotics, pneumonia and the immune response to stroke outcome.
P50
Q28262545-217E92D6-71B0-4658-AEA8-F94185CDE03FQ28305061-F546842C-7BA4-4F87-B30B-FDD45155C0F4Q30577527-B29EA824-177F-4902-96D5-6B32BCEECBABQ31126967-A299927D-C495-460C-9E23-972CC91CB079Q33651624-93399608-D11A-4140-826F-96DD76071457Q33694337-A70629C6-47FC-40B2-8CA2-E2AE1A0E7C00Q33887000-8E6D6E8E-46EE-4F13-9F6C-2AE0EA2365C7Q34049621-A296DBED-6E5E-44E4-B6F2-8E324D7EB00AQ34049644-B7FE9C94-4F02-4331-9310-D47222274FADQ34151647-141257E9-B318-4117-BE26-C7946976CD1DQ34153140-6EAFE090-A049-49F7-927B-8225F040643BQ34164095-D0E1A1B2-FF3B-4CD8-8B64-C89EA74FBEE5Q34238350-B23F9310-0ED6-4A34-8270-E4610BF9F56CQ34260366-E8F3C01F-ADB3-46E2-9DC8-3011E91B6259Q34473891-14D487B0-7E6F-4DE7-8E02-C094387944F3Q35177506-90BBEFF4-CAD1-456F-B5B4-1BF7A57A03C2Q35422154-5D7361F5-3947-45A3-9FDB-FCD4E8FC137FQ35456704-313C1EC0-529F-4FAE-A6FD-4FF03AD213BBQ35582407-92FFB6DF-DB9D-4FA2-BC9B-3EF30A27827AQ35711431-7DB05AB9-0DF8-41F1-B0F2-9B22F3940FF3Q35729575-08D58AF1-6487-497E-B6FF-9C656A8D4F93Q35862761-0BAD279D-17C9-4C4B-8B94-DE17D08E829AQ36091174-449CF3C3-A67C-4259-94E1-E5AC4264EDF1Q36195292-F04EBD5E-05A3-411E-8A6E-7EA148008BACQ36234457-3F74781E-4426-47C8-AD16-610B7A162872Q36303569-F7C99687-991D-4E74-BF25-5D792C3CEDE0Q36425972-74FD49B5-38FB-4423-B09B-0157D5DD1139Q36489511-82267BFD-F6AC-4CFE-9CC5-A15BBDBE0624Q36721681-14BEABCF-EB90-4DC2-8CE5-644A2726DE65Q37033365-59B92A90-EFE2-480F-A942-12D6EA558F42Q37052903-E5E27A88-4494-472E-94AE-B047A4D2795BQ37186436-92197DA9-23C3-4FD1-8242-848A2BB053B9Q37244830-C7E4076F-E864-43E1-B301-218A541060A1Q37339885-7D381AA7-ADD3-4844-94AC-AE0115667329Q38121119-9FDF9385-7E65-4F0D-A388-DBF684D66B3BQ38236852-55BE7E3F-54E5-46E5-954D-7A35205A4776Q38871034-DEBC5EB4-1C7D-4C9A-85DE-AEEAA288D26CQ38930435-F7FE71E4-DFC4-4604-B6AB-BE50A778BD54Q39331271-62129A8C-69A5-4757-AD57-E75D7F873731Q39729591-A74C7FEA-5887-495F-83A8-ADA6025547EE
P50
description
researcher ORCID ID = 0000-0002-8310-4846
@en
wetenschapper
@nl
name
Kyra Becker
@ast
Kyra Becker
@en
Kyra Becker
@es
Kyra Becker
@nl
type
label
Kyra Becker
@ast
Kyra Becker
@en
Kyra Becker
@es
Kyra Becker
@nl
prefLabel
Kyra Becker
@ast
Kyra Becker
@en
Kyra Becker
@es
Kyra Becker
@nl
P1153
7401803178
P31
P496
0000-0002-8310-4846